The investigators sought to answer the pivotal question of whether risk based on these clinically validated scores modified LCZ696's treatment.
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predictors of all-cause mortality, including age, male sex, diabetes, systolic blood pressure, left ventricular ejection fraction, obstructive lung disease, renal dysfunction, and the use of neurohormonal antagonists (7). A simple integer score was derived for each patient, with a maximum of 57 points. Similarly, the EMPHASIS-HF risk score included 10 independent risk factors, such as hemoglobin, heart rate, and prior HF hospitalization; the maximal possible score was 12 points (8) . Patients were divided into 5 quintiles of MAGGIC risk and 4 quartiles of EMPHASIS-HF risk.
The primary composite endpoint of death or HF hospitalization, those 2 components, and all-cause mortality were all analyzed for each risk group and by treatment type using Cox regression modeling.
Not surprisingly, patients in higher quintiles were more likely to have NYHA functional class III or IV symptoms and additional medical comorbidities.
When the MAGGIC score was examined as a continuous variable, an increase of 1 point in the overall score was associated with a 6% increased risk for the primary endpoint and a 7% increased risk for cardiovascular death. Importantly, the benefit of LCZ696 over enalapril for the primary endpoint was similar across the entire spectrum of risk. Analysis using the EMPHASIS-HF score produced similar findings.
Whether analyzed as continuous or categorical variables, LCZ696 provided the greatest absolute benefit in those at highest risk. The investigators conclude that, within the overall PARADIGM-HF population, there was a substantial subset with much to gain from angiotensin receptor and neprilysin inhibition over a relatively short period of time (6) .
Although these findings are impressive, various limitations must be considered. First and foremost, this was a non-pre-specified post-hoc analysis with the inherent limitations and potential for unrecognized bias. In addition, trial patients were generally younger (mean age 64 years), had better preserved systolic blood pressures, and had less renal dysfunction than many "real-life" HF populations. Nonetheless, this is a good "problem" to have, as a new class of agents with major benefits is on the horizon and should substantially improve our approach to managing chronic systolic HF.
